Skip to main content
OpenTrials
Completed

NCT Number: NCT03287466

Targeted OXYgen Therapy in Critical Illness

The investigators propose to conduct a feasibility, multi-centre, randomised controlled trial of targeted oxygen therapy in adult critically ill patients receiving mechanical ventilation via an endotracheal tube as part of their treatment for respiratory failure. Participants will be allocated to either a normal blood oxygen target group or a lower than normal blood oxygen target group. The primary purpose of the study will be to assess the feasibility of recruiting complex patients who lack capacity into a clinical trial in which oxygenation is being assessed, and that the clinicians responsible for these patients are able to deliver the intervention effectively. The safety of using a lower than normal blood oxygen target will also be assessed and blood samples taken for subsequent investigation of the biological mechanisms underlying the observed changes.

Participants will be randomised (1:1) into either an intervention or control group. The intervention in this trial is tightly controlled administration of oxygen to patients to achieve a haemoglobin oxygen saturation (SpO2) of 88-92%. The control group will also have tightly controlled oxygen administration, but to achieve an SpO2 of 96% or above. The target for the control group represents a normal SpO2, whilst that in the intervention group is lower than what is considered to be normal. It should be noted that although lower than normal, this SpO2 is close to what the general public experience when travelling by pressurised aircraft as the fractional inspired oxygen concentration in that situation is only 0.15-0.17 (15-17%).

The controlled oxygen administration would commence as soon as possible after admission to the critical care unit and end following removal of the participant's artificial breathing tube. The researchers and clinical team cannot be blinded to treatment allocation, due to the nature of the intervention. Those analysing the data will be blinded to the intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Royal Free Hospital

London, NW3 2QG, United Kingdom

About this study

The investigators aim is to determine whether revising standard targets for blood oxygen levels in patients requiring artificial ventilation on a critical care unit is feasible and whether this affects specific blood biomarker levels.

Investigators in this area of expertise currently lack the information necessary to determine how much oxygen should be given to adult critically ill patients on a mechanical ventilator to assist their breathing in order to achieve the best clinical outcomes i.e. minimal morbidity and mortality. Excessive oxygen administration (both its concentration and duration) and hyperoxaemia (an excessively high blood oxygen level) are known to be harmful to critically ill patients. The reason for this is that oxygen in high concentration is toxic, because it results in the release of molecules called reactive oxygen species (ROS). ROS lead to a state known as 'oxidative stress', in which cells and tissues are rapidly destroyed by these destructive molecules.

The difficulty with treating critically ill patients is that they are usually extremely unwell, requiring artificial ventilation to support their breathing. Unfortunately, these patients appear to be exceptionally prone to the harms of oxidative stress, leading to permanent damage of their lungs. Yet it is precisely this group of patients who require high concentration oxygen to keep their blood oxygen levels within the normal. It has therefore been hypothesised that using lower blood oxygen targets than usual may be beneficial to these patients through the avoidance of excessively high concentrations of oxygen. The investigator proposes that in mechanically ventilated critically ill patients harm (morbidity and mortality) will be reduced by using 'targeted oxygen therapy' (TO2T) to achieve lower blood oxygen levels than normal when compared to standard practice (normal blood oxygen levels). The levels are only moderately lower than normal and well within what most clinicians would consider to be safe in these patients.

Prior to any large-scale study, it is important to understand if this approach to managing critically ill patients is feasible. This prospective, dual site randomised controlled trial will therefore establish whether it is possible to conduct a trial in which blood oxygen levels are carefully titrated by the critical care team, to achieve specific targets. Participants will be allocated into one of two groups: i) normal blood oxygen levels, and ii) low blood oxygen levels. For the time that participants are artificially ventilated by a breathing (endotracheal) tube, they will remain in their allocated treatment group. Information will be collected from the patient's charts and records during their stay on the CCU to assess the impact of the treatment. A series of blood samples will also be collected from participants to quantify the degree of oxidative stress through the measurement of several specific biomarkers. A total of 60 patients will be enrolled at two sites.

As oxygen is a drug that is administered to almost every patient admitted to a critical care unit (CCU), it is imperative that decisions regarding oxygenation are based upon evidence rather than conjecture. Limited work has been undertaken to date to understand whether lowering blood oxygen levels is achievable in this complex patient group. The information from this study will be used to design a subsequent much larger study to fully evaluate whether TO2T to achieve lower blood oxygen levels saves lives in critically ill patients. If lower blood oxygen levels improve survival in critically ill patients implementation of this intervention could have an immediate and cost-effective impact across the entire National Health Service.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Unplanned admission to a critical care unit
  • 18 years of age and above (no upper age limit)
  • Respiratory failure forms part of the admission diagnosis
  • The patient is mechanically ventilated via an endotracheal tube
  • The patient is expected to receive mechanical ventilation for > 24 hours

Exclusion criteria

  • Admission following surgery (elective or unplanned)
  • Those patients expected to die within 24 hours of admission to ICU *
  • Pregnant females
  • Admission post-cardiac arrest
  • Admission post trauma (including traumatic brain injury)
  • Known sickle cell trait or disease
  • Ongoing significant haemorrhage or profound anaemia
  • Severe peripheral vascular disease
  • Severe pulmonary hypertension
  • Other medical conditions where mild hypoxaemia would be contra-indicated ***
  • Patients participating in other interventional clinical trials
  • As determined by the responsible clinical team ** As determined by the responsible clinical team and /or research team

Treatment and study plan

Oxygen

Drug

targeted oxygen therapy

Primary outcomes

  1. Feasibility to recruit

    Time frame: 15 Months

    Ability to recruit

Secondary outcomes

  1. Measurement of arterial blood gases

    Time frame: up to 21 days

    Measurement of arterial blood gases

  2. Measurement of oxygen saturation

    Time frame: up to 21 days

    Measurement of oxygen saturation

  3. Measurement of fraction of inspired oxygen

    Time frame: up to 21 days

    Measurement of fraction of inspired oxygen

  4. Time to extubation / detachment from mechanical ventilation

    Time frame: up to 21 days

    Time to extubation / detachment from mechanical ventilation

  5. Mechanical ventilation free days on ICU

    Time frame: up to 21 days

    Mechanical ventilation free days on ICU

  6. Measurement of blood pressure

    Time frame: up to 21 days

    Measurement of blood pressure

  7. Measurement of heart rate

    Time frame: up to 21 days

    Measurement of heart rate

  8. Measurement of cardiac rhythm

    Time frame: up to 21 days

    Measurement of cardiac rhythm

  9. Measurement of cardiac output and stroke volume (if measured)

    Time frame: up to 21 days

    Measurement of cardiac output and stroke volume (if measured)

  10. Measurement of vasopressor doses

    Time frame: up to 21 days

    Measurement of vasopressor doses

  11. Measurement of inotrope doses

    Time frame: up to 21 days

    Measurement of inotrope doses

  12. Measurement of daily fluid balance

    Time frame: up to 21 days

    Measurement of daily fluid balance

  13. Measurement of inotrope free days on ICU

    Time frame: up to 21 days

    Measurement of inotrope free days on ICU

  14. Measurement of vasopressor free days on ICU

    Time frame: up to 21 days

    Measurement of vasopressor free days on ICU

  15. Measurement of Urea

    Time frame: up to 21 days

    Measurement of Urea

  16. Measurement of creatinine

    Time frame: up to 21 days

    Measurement of creatinine

  17. Measurement of urine output

    Time frame: up to 21 days

    Measurement of urine output

  18. The need for renal replacement therapy

    Time frame: up to 21 days

    The need for renal replacement therapy

  19. Renal replacement therapy free days on ICU

    Time frame: up to 21 days

    Renal replacement therapy free days on ICU

  20. Measurement of transaminases

    Time frame: up to 21 days

    Measurement of transaminases

  21. Measurement of blood clotting values

    Time frame: up to 21 days

    Measurement of blood clotting values

  22. Measurement of bilirubin

    Time frame: up to 21 days

    Measurement of bilirubin

  23. Measurement of blood lactate

    Time frame: up to 21 days

    Measurement of blood lactate

  24. Measurement of Troponin

    Time frame: up to 21 days

    Measurement of Troponin

  25. Adverse events

    Time frame: 90 days

    Adverse events

  26. SOFA score change

    Time frame: up to 21 days

    Sequential Organ Failure Assessment (SOFA) score change

  27. APACHE II score change

    Time frame: up to 21 days

    Acute Physiology and Chronic Health Evaluation (APACHE) II score change

  28. Length of ICU stay

    Time frame: up to 21 days

    Length of stay in intensive care unit

  29. Length of hospital stay

    Time frame: 90 days

    Length of hospital stay

  30. Mortality rates

    Time frame: 90 days

    Days alive

  31. Days alive out of Hospital

    Time frame: 90 days

    Days alive out of Hospital

Sponsors and collaborators

Lead sponsor

University College, London

Other

Collaborators

  • National Institute for Health Research, United Kingdom
  • Royal Free Charity
  • Royal Free Hospital NHS Foundation Trust
  • University Hospital Southampton NHS Foundation Trust

Registry information

Official study title

A Randomised Controlled Trial of Targeted Oxygen Therapy in Mechanically Ventilated Critically Ill Patients

Acronym: TOXYC

Important dates

Study start
2018
Primary completion
2019
Study completion
2020
First posted
Sep 19, 2017
Registry last updated
Sep 29, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.